Terns scores $80M in Series B financing led by Vivo, OrbiMed
Transpacific biotech upstart Terns Pharmaceuticals, which is focused on developing treatments for NASH and cancer, has closed $80 million in Series B financing as it prepares to shepherd its lead experimental drugs to the clinic.
The new round of financing adds to the $30 million the company secured from Lilly Asia Ventures that led to an in-licensing deal with the ventures’ parent company Eli Lilly $LLY involving three NASH assets this April, including its lead investigational products TERN-101 and TERN-201.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
